Psychedelics in Therapy

Historical Context and Modern Revival

Psychedelic-assisted therapy emerged as a promising field in the 1950s and 1960s, with researchers exploring medicines like LSD for various mental health struggles. However, due to stringent regulations and societal stigma, this line of research faced a significant hiatus. In recent years, there has been a renewed interest in these therapies, recognizing their potential to revolutionize mental health treatment (Duke-Margolis Center for Health Policy, 2022).

Shifting Paradigms in Mental Health Treatment

The resurgence of psychedelic-assisted therapy represents a paradigm shift in mental health care. Unlike traditional pharmacological approaches that often require daily medication, psychedelic therapies offer the potential for profound and lasting change with just a few supervised sessions. This novel approach challenges conventional understandings of mental health treatment and opens new avenues for healing previously treatment-resistant conditions.

How Psychedelics Affect the Brain

Psychedelics have been shown to promote neuroplasticity, the brain's ability to form new neural connections. This process involves increased synaptic growth and the formation of new dendritic spines. Research suggests that medicines like psilocybin, ketamine, and LSD can stimulate the growth of new neurons; potentially facilitating cognitive flexibility and emotional processing (Ly et al., 2018).

Altered Default Mode Network Activity

One significant effect of psychedelics is their impact on the default mode network (DMN), a group of brain regions active during self-referential thinking. Psychedelics temporarily disrupt the DMN's normal functioning, leading to altered consciousness (Carhart-Harris et al., 2014). This disruption may allow for new perspectives and insights, breaking habitual thought patterns that often accompany depression and anxiety (Carhart-Harris et al., 2017).

Neurotransmitter Modulation

Psychedelics primarily act on serotonin receptors, particularly the 5-HT2A receptor. This interaction leads to a cascade of neurochemical changes, including increased glutamate release and altered dopamine signaling (Vollenweider & Preller, 2020). The complex interplay of these neurotransmitters contributes to the profound cognitive and emotional effects experienced during psychedelic-assisted therapy sessions.

The Role of Psychotherapy in Psychedelic-Assisted Treatments

Psychedelic-assisted therapies have shown promising results in treating depression and anxiety. Recent studies indicate that medicines like ketamine, psilocybin and MDMA (when used in controlled therapeutic settings) can lead to significant reductions in symptoms (Carhart-Harris & Goodwin, 2017; Feder et al., 2020; Mithoefer et al., 2019). These treatments often work by promoting neuroplasticity and altering negative thought patterns, offering relief where traditional methods have failed (Daws et al., 2022). In addiction treatment, psychedelics are emerging as powerful tools. Psilocybin-assisted therapy has shown efficacy in treating alcohol use disorder, helping patients break entrenched patterns of substance abuse (Bogenschutz et al., 2015).

Psychedelics can induce intense and sometimes challenging experiences. Without appropriate therapeutic support, individuals may struggle to process these experiences effectively. Psychotherapy provides a safe and supportive environment for clients to explore and integrate the emotions, thoughts, and memories that surface during psychedelic sessions. This integration process is essential for translating psychedelic-induced insights into meaningful and lasting psychological change (Levin & Davis, 2023).​

Ensuring Safety and Ethical Standards

Therapists play a key role in preparing clients for the psychedelic experience, offering guidance during sessions, and assisting with post-session integration. This comprehensive support helps shift the concept that there can be a "bad trip"; instead creating a space where challenging experiences are welcomed (Mithoefer et al., 2023).​

Facilitating Emotional and Cognitive Processing

Psychedelics can lower psychological defenses, bringing repressed emotions and memories to the forefront of consciousness. Psychotherapy provides a framework for individuals to confront and process these emergent experiences. Clients can work through unresolved issues, leading to emotional release and cognitive restructuring. This process is particularly beneficial for complex trauma and PTSD, where integrating traumatic memories is a central component of healing (Carhart-Harris et al., 2019).​

Supporting Lasting Behavioral Change

The insights gained during psychedelic experiences can be profound, but without proper integration, they may not lead to sustained behavioral change. Psychotherapy assists folks in translating these insights into actionable steps, reinforcing new patterns of thinking and behavior (Carhart-Harris et al., 2019).

Clinical Trials and Emerging Research: Promising Results and Future Directions

Recent clinical trials have shown remarkable promise for psychedelic-assisted therapies. Studies involving psilocybin, MDMA, and ketamine have demonstrated significant efficacy in treating depression, PTSD, and addictions (Mitchell et al., 2021; Nutt & Carhart-Harris, 2021). For instance, a landmark study found that MDMA-assisted therapy led to a significant reduction in PTSD symptoms (Mitchell et al., 2021).

Neuroplasticity and Brain Function

Emerging research suggests that psychedelics may promote neuroplasticity, potentially "rewiring" maladaptive neural pathways. Functional MRI studies have revealed increased connectivity between brain regions following psychedelic administration, offering insight into the mechanisms behind their therapeutic effects (Daws et al., 2022; Preller & Vollenweider, 2019)..

Future Directions and Challenges

Researchers are exploring optimal dosing regimens, integration practices, and other potential applications (Reiff et al., 2020). However, regulatory hurdles and stigma remain significant challenges to widespread adoption (Nutt et al., 2020). As the field progresses, ethical considerations surrounding accessibility and equitable distribution of these transformative treatments will continue to be evaluated (Williams & Labate, 2020).

References:

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144

Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology, 42(11), 2105–2113. https://doi.org/10.1038/npp.2017.84

Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Bolstridge, M. (2019). Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 176(7), 560–561. https://doi.org/10.1176/appi.ajp.2019.19010035

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109

Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344. https://doi.org/10.1124/pr.118.017160

Daws, R. E., Timmermann, C., Giribaldi, B., Sexton, J. D., Wallis, C., Erritzoe, D., … & Carhart-Harris, R. L. (2022). Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 28(4), 844–851. https://doi.org/10.1038/s41591-022-01744-z

Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., … & Charney, D. S. (2020). Efficacy of ketamine in the treatment of posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 71(6), 681–688. https://doi.org/10.1001/jamapsychiatry.2020.0929

Levin, A. W., & Davis, A. K. (2023). What Matters Most in Psychedelic-Assisted Psychotherapy? Psychiatric Times. https://www.psychiatrictimes.com/view/what-matters-most-in-psychedelic-assisted-psychotherapy

Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Zarandi, S. S., Sood, A., Paddy, M. R., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., ... & Marmar, C. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3

Mithoefer, M. C., Mithoefer, A., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., … & Doblin, R. (2019). MDMA-assisted psychotherapy for PTSD: A phase 3 clinical trial. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3

Mithoefer, M. C., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., & Holland, J. (2023). Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based Approaches. American Journal of Psychiatry, 180(6), 456–457. https://doi.org/10.1176/appi.ajp.20230665

Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020). Psychedelic psychiatry’s brave new world. Cell, 181(1), 24–28. https://doi.org/10.1016/j.cell.2020.03.020

Nutt, D., & Carhart-Harris, R. (2021). The current status of psychedelics in psychiatry. JAMA Psychiatry, 78(2), 121–122. https://doi.org/10.1001/jamapsychiatry.2020.2171

Preller, K. H., & Vollenweider, F. X. (2019). Phenomenology, structure, and dynamic of psychedelic states. Current Topics in Behavioral Neurosciences, 36, 221–256. https://doi.org/10.1007/7854_2017_474

Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., & McDonald, W. M. (2020). Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry, 177(5), 391–410. https://doi.org/10.1176/appi.ajp.2019.19010035

Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 21(11), 611–624. https://doi.org/10.1038/s41583-020-0367-2

Williams, M. T., & Labate, B. C. (2020). Diversity, equity, and access in psychedelic medicine. Journal of Psychedelic Studies, 4(1), 4–9. https://doi.org/10.1556/2054.2019.016